GSK's Jemperli approved for advanced endometrial cancer in Singapore [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
The programmed death receptor-1 (PD-1)-blocking antibody Jemperli attaches to the PD-1 receptor and blocks its interaction with the PD-L1 and PD-L2 ligands. The approval allows for the use of Jemperli, in combination with carboplatin and paclitaxel, for patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer. It expands Jemperli's indication to an earlier stage in treatment, offering a new frontline immuno-oncology option. It was previously approved as monotherapy for dMMR recurrent or advanced endometrial cancer patients after a platinum-containing regimen. The recent decision by the Singapore HSA is based on interim analysis from the RUBY Phase III trial, which showed a 72% reduction in disease progression or death risk in the dMMR/MSI-H population. The trial is a comprehensive study evaluating dostarlimab in combination with chemotherapy. Part 1 of the trial, which informed the HSA's decision, met its primary endpoin
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- Anaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Anaptys Announces Participation in November and December Investor ConferencesGlobeNewswire
- AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 11/5/24 - Beat
ANAB
Sec Filings
- 11/5/24 - Form S-3
- 11/5/24 - Form 10-Q
- 11/5/24 - Form 8-K
- ANAB's page on the SEC website